[Recombinant monoclonal antibodies for the treatment and prevention of viral infections]

Abstract

Recombinant monoclonal antibodies (mAB) are a new class of medicinal preparations with the potential for wide application to the treatment of viral infections. Marked progress in the development of therapeutic mAB against respiratory syncytial influenza A viruses, West Nile virus, and some others has been achieved in recent years in contrast to HIV and hepatitis C pathogens. The main obstacle hampering this work is great heterogeneity and diversity of these viruses. Gene engineering technologies make it possible to modify mAB, modulate their efficacy, and create bi-specific mAB. This review presents data on the development and prospects for the application of mAB to prevent and treat viral infections.